ABSTRACT
INTRODUCTION

57
Overweight and obesity result from abnormal adipose deposition and function and are 58 considered as major pathophysiological symptoms of metabolic syndrome (Olufadi & Byrne, 59 2008) . Originating from insulin resistance, metabolic syndrome may be reflected by several 60 clinical manifestations such as atherosclerosis, hyperglycemia, dyslipidemia, hypertension, 61 reduced high-density lipoprotein cholesterol and type 2 diabetes mellitus (Furukawa et al., 62 2017) . Based on typical pathological symptoms, broadly defined as excessive fat mass in the 63 body (specifically the abdomen), the prevalence of obesity has rapidly increased during the last 64 two decades (Kobyliak et al., 2017) . In spite of intensive 65 research input in recent history, deeper understanding of pathogenesis and knowledge on the 66 underlying mechanisms of obesity are still limited, while, in fact, the causality of obesity has been 67 suggested from different viewpoints and disciplines of science such as genetics, endocrinology 68 and psychology (Schwartz et al., 2017) . 69
Following up on classical approaches, recent studies show that microbiota can play a key 70 role in host obesity and metabolic syndrome (Gérard, 2016) . Thereby, new clinical diagnostic 71 perspectives were opened on the influence of gut microbiota on the status of metabolic disorders. 72
Numerous studies have reported on qualitative and quantitative discrepancies in microbiota of 73 the gastrointestinal tract (GIT) when comparing healthy subjects with people suffering from 74 metabolic diseases (Turnbaugh et al., 2006; Turnbaugh et al., 2008; Ley et al., 2005; Cani & 75 Delzenne, 2009; Armougom et al., 2009) . 76
There is general consensus that probiotics support the host gut microbiota balance, and 77 scientific evidences are steadily accumulating regarding the beneficial impact of probiotics on 78 human health, including immune disorders, inflammatory bowel disease, type 2 diabetes and 79 atherosclerosis (Amar et al., 2011; Kim et al., 2016; Ritze et al., 2014; Schroeder et al., 2018; 80 Vemuri, Gundamaraju & Eri, 2017) . Various modes of probiotic action were elucidated by using 81 in vitro studies (including in vitro models) while efficacy was investigated by in vivo studies and 82 clinical trials. Along with therapeutic benefits, anti-obesity effects of probiotics have been 83
reported recently (Kadooka et al., 2010; Park et al., 2016; Wang et al., 2015; Woodard et al., 84 clinical trials, and scientific evidence for a "minimal dose effect level" remains relatively sparse 86 (Tanentsapf, Heitmann & Adegboye, 2011; Raoult, 2009; Mekkes et al., 2013) . The concept of a 87 minimal effective dose is complicated due to the large (and diverse) number of microbial and 88 host-related factors (Salminen et al., 1998) , and will also depend on the kind of key criteria and 89 the "end-points" selected. The dose of intolerance is generally considered to be high, thus, 90 allowing a relatively broad "therapeutic window" (Collins, Thornton & Sullivan, 1998) , it may be 91 difficult to find a suitably effective low dose above the minimal level. Yet, precisely defining an 92 effective dose has remained an arbitrary issue, and thus the pragmatic suggestion by an 93 FAO/WHO Working Group (FAO/WHO, 2002) that "The suggested serving size must deliver the 94 effective dose of probiotics related to the health claim". Convincingly delivering this kind of 95 evidence has remained difficult until this day, in particular for commercial distribution of (food 96 or pharmaceutical) strains claimed to be probiotics. In an early report Perdigón, Alvarez & de 97 Ruiz Holgado (1991) suggested a dose related impact of Lactobacillus casei on the secretory 98 immune response and protective capacity in intestinal infections. A placebo-controlled study 99 designed to evaluate the therapeutic value of four different non-antibiotic preparations 100 (including Saccharomyces boulardii, and heat-killed microbial strains) indicated a non-significant 101 dose dependency for either prophylaxis or treatment of traveller's diarrhoea (Kollaritsch et al., 102 1989; Kollaritsch et al., 1993 ). Yet, substantial evidence supports the principle of dose 103 dependency of probiotics to modulate systemic and mucosal immune function, improve 104 intestinal barrier function, alter gut microbiota, and exert metabolic effects on the host, also in 105 a strain dependent manner (Alemka et al., 2010; Madsen, 2012) . Everard et al. (2011) reported 106 a dose-dependent immunomodulation of human DCs by the probiotic Lactobacillus rhamnosus 107 Lcr35, leading, at high doses, to the semi-maturation of the cells and to a strong pro-108 inflammatory effect. 109
In this study we administered three different ten-fold doses of three different L. sakei 110 strains separately to a diet induced obese C57BL/6 murine model and monitored body weight 111 during the full experimental period. Organ weights and serum biomarkers were monitored to 112 elucidate the dose dependent anti-obesity effect of three different Lactobacillus sakei strains. 113
114
MATERIALS AND METHODS
115
The animal study was approved by the Ethical Committee of KPC Ltd. in Korea (P150067). Five 116 weeks old, specific pathogen free (SPF) male C57BL/6 mice were supplied from Orient Bio, 117
Korea. High fat diet (Research Diets D12492) (HFD), low fat diet (Cargill Agri Purina Inc., Rodent 118
Chow) (LFD) and autoclaved tap water were provided ad libitum, while the animals were housed 119 at 23 °C, 55 ± 10 % humidity, in a 12 h light/dark cycle. All 120 mice were separated into 12 120 different groups each receiving different treatments (Table 1) . 121 122 
124
The experiment comprised one week of adaptation followed by six weeks of obesity 125 induction using HFD while the LFD group was maintained on LFD feeding. After six weeks as 126 obesity induction period, each group was treated with either the PBS suspended microbial culture, 127 PBS suspended Orlistat as chemical control or only PBS as negative control, twice a day at the 128 same time (10:00 and 17:00) for seven weeks. On the last day of the experiment, the mice were 129 sacrificed by dislocation of the cervical vertebrata. times with PBS. Each strain was prepared in an approximate number of 1 X 10 10 CFU/ml using a 140 mathematical equation derived from a pre-optimised standard curve (data not shown) using 141 optical density by SPECTROstar Nano (BMG Labtech, Durham, USA). A stock suspension of 1 X 142 10 10 CFU/ml was prepared of each strain, then diluted ten-fold to 1 X 10 9 and 1 X 10 8 CFU/ml, 143 respectively, and finally suspended in 300 µl of PBS to be administered to each mouse by oral 144
gavage. 145
Experimental determinants were statistically calculated using ANOVA and Dunnett's multiple 146 comparison test to distinguish the level of significance based on probability of 0.05 (*), 0.01 (**) 147 and 0.001 (***). 148
149
RESULTS
150
Three different doses (10 8 -10 10 ) of the three L. sakei strains (CJB38, CJB46 and CJLS03) were 151 orally administered to high fat diet induced obese C57BL/6 mice for 7 weeks, and body weight 152 and food consumption were measured daily. During the test period, three strains were found to 153 exhibit weight loss compared to the HFD group (Fig. 1 b, c, d) . LFD, Orlistat, all of the CJB46 154 group, and medium and high dose of the CJLS03 groups showed significantly lower weight 155 7 increase compared to the HFD group. The weight loss was not dependent of the dose of CJB38 156 or CJB46 while CJLS03 showed a dose-dependent weight reduction effect and CJLS03 H showed 157 the highest efficacy of all groups (Fig. 1 e) . The onset time of weight loss showed significance 158 compared to HFD at days 4, 21, 21 and 7 for the Orlistat, CJB38, CJB46 and CJLS03 groups, 159 respectively (data not shown). The daily dietary intake was significantly higher in the LFD, 160
Orlistat and CJLS03 M groups compared to the HFD group (Fig. 1 f) . 161
Serum biochemical analysis showed an overall increase in the lipid profile (TC, TG, HDL, 162 LDL), liver (AST) and the glucose level of the HFD group compared to the LFD group, 163 demonstrating that a high fat diet intake may impact various biomarkers associated with 164 pathophysiological symptoms of obesity (Fig. 2) . Compared to the HFD group, the serum TG level 165 decreased in all test groups (Fig. 2 a) while the LDL level was significantly reduced in all test 166 groups except CJB46 H (Fig. 2 e) . Significant reduction of TC was only detected in LFD, Orlistat 167 and in the groups treated with higher doses (M and H) of L. sakei CJB38 H, CJB46 M, CJB46 H, 168 CJLS03 M and CJLS03 H (Fig 2 c) . In particular, the CJLS03 group, shown to be superior regarding 169 weight gain inhibition, appears to be effective in a dose dependent manner (Fig. 2 a, b, c) . HDL 170 levels were not significantly different from the HFD group in all the test groups, however, all L. 171 sakei treated groups except CJB46 L, CJLS03 M and CJLS03 H showed significant increase when 172 the ratio of HDL to total cholesterol level was calculated (data not shown). Serum AST values 173 (indicating liver function) were found to be approximately 1.7 times higher for the HFD 174 compared to the LFD group (Fig. 2 f) , while the Orlistat group showed no significant change in 175
AST level compared to the HFD group. All three groups receiving the L. sakei strains showed 176 noticeable decrease of AST levels with a dose-dependent reduction in the CJLS03 groups, which 177 was significant in the CJLS03 H group when compared to the HFD group (Fig. 2 f) . CJLS03 showed 178 the highest overall effectivity and a dose dependent anti-obesity function; at the same time, it 179 induced a dose-dependent improvement of serum obesity associated biomarkers and liver 180
function. 181
Compared to HFD the LFD group showed significantly lower weights of epididymal, 182 mesenteric, subcutaneous and brown adipose tissues while insignificant organ weightdifferences were measured in liver and femoral muscles (Fig 3) . Every dose of all three strains of 184 L. sakei and the Orlistat group resulted in significantly lower subcutaneous adipose tissue weight 185 while only CJLS03 H showed significant reduction of visceral adipose tissue including epididymal 186 and mesenteric adipose tissue, when compared to the HFD group (Fig. 3 a, b, c) . CJLS03 M 187 treatment significantly reduced epididymal adipose tissue weight when compared to the HFD 188 group (Fig 3 a) . These results suggest that the three different L. sakei strains inhibited the 189 accumulation of subcutaneous adipose tissue but that the CJLS03 group responded by dose 190 dependent reduction of visceral adipose tissues including the epididymal and mesenteric 191 adipose tissues (Fig. 3a, b) . Orlistat and L. sakei treatment did not result in significant weight 192 differences regarding brown adipose tissue, liver and femoral muscle (Fig 3 d, e, f) . 193 
DISCUSSION
213
The anti-obesity influence of administered probiotics is a heavily debated issue, yet, an 214 indisputable fact is that host gut microbiota is exercising a leverage over energy efficiency and 215 adipose tissue accumulation (Kobyliak et al., 2017; Greiner and Bäckhed, 2011; Delzenne et al., 216 2011) ; at the same time, probiotics have been reported to impact on host microbiota in a 217 positive way. 218
Probiotic administration increasingly enjoys consideration as a promising approach for 219 beneficially modulating the host microbiota (Jia et al., 2008; Steer et al., 2000) . Numerous 220 reports confirmed the beneficial effects of specific probiotic strains against diarrhoea and 221 inflammatory bowel diseases (Ahmadi, Alizadeh-Navaei & Rezai 2015; Gionchetti et al., 2000; 222 Ouwehand, Salminen & Isolauri, 2002) . Recently, anti-obesity effects of probiotics were also 223 reported and confirmed in clinical trials and animal models (Kim et al., 2016; Alard et al,. 2016; 224 Wang et al., 2015; Ji et al., 2012; Kadooka et al., 2010) . Kadooka et al. (2010) investigated the 225 anti-obesity effect of the probiotic L. gasseri SBT2055 by conducting a double-blind, 226 randomised, placebo-controlled intervention trial with 87 overweight and obese subjects for 12 227 weeks. The data confirmed that the abdominal visceral and subcutaneous fat area, weight, BMI, 228 as well as waist and hip measures were significantly reduced in the group consuming the 229 probiotic. In another study (Woodard et al., 2009 ) 44 morbid obese patients were operated for 230 weight loss by surgery (gastric bypass surgery) and were randomly divided in a probiotic 231 administered group and a control group. A significantly higher weight loss was recorded in the 232 group receiving the probiotic. Park et al. (2013) reported a significant weight reduction of a 233 C57BL/6 mice model after administering L. curvatus HY7601 and L. plantarum KY1032, however, 234 faecal microbiota modulation of major groups such as Firmicutes and Bacteroidetes was not 235
monitored. 236
One of the major hurdles for an accurate clinical trial is to understand the effective dose 237 of a probiotic at a strain specific level. Selecting the correct dose of a probiotic for a specific 238 purpose such as the alleviating of diarrhoea was suggested in various studies, yet, there is a 239 general lack of scientific proof of a concept to define the functional dose of a probiotic 240 (Kollaritsch et al., 1993; Kollaritsch et al., 1989; Islam, 2016) . Chen et al. (2015) used 5 different 241 tenfold doses of L. acidophilus in a colitis induced animal model and reported 10 6 CFU/10g of 242 the animal weight as the most effective application level for modulating the bacterial profile in 243 the distal colon. 244
In our study we have monitored the dose dependent anti-obesity effects of three 245 different strains of L. sakei and found only one strain, CJLS03, to show a dose dependent anti-246 obesity effect while the anti-obesity impact of the other two strains was found to be dose 247 independent. Adipose tissues were reduced relative to weight gain and triglyceride and total 248 serum cholesterol showed the most significant reduction in the L. sakei treated groups 249 compared to the HFD control group. 250
251
CONCLUSIONS
252
This in vivo investigation showed that beneficial effects of putative probiotics are both strain 253 specific and dose related. For only one (CJLS03) out of three L. sakei strains an anti-obesity effect 254 could be detected, which, at the same time, was found to be dose dependent. The highest of 255 three doses (1 x 10 10 CFU/day) of CJLS03 gave the most favourable (significant) biomarker 256 related effects with regard to cholesterol and triglyceride reduction, when compared to the HFD 257 control. 
